The MCCC employs both internal and external review mechanisms to inform the strategic decisions made by the Center and to provide feedback necessary for ongoing evaluation of the effectiveness of those decisions. The MCCC's efforts in this regard are broad and encompassing, employing a variety of strategies. Processes are in place for overall strategic planning, review of the established and developing programs, and review of the established and developing shared facilities. They are guided by a clear vision for the Center developed by the Center Director and Senior Leadership and facilitated by Cancer Center Administration. The vision is consistent with the goals of the NCI Centers Program and the mission of the Mayo Clinic, and built upon a careful assessment of the current and future scientific opportunities in cancer research and how the unique capabilities of Mayo Clinic can be leveraged to define areas of particular strength. This overall vision is used to help evaluate recommendations brought forward by leaders of programs and shared facilities - and even individual Center members. These efforts thus inform site and center-wide priorities for portfolio and programmatic stabilization and growth, integration, investment in infrastructure - notably shared resources, recruitment, health disparities and facilities, and use of discretionary resources including CCSG Developmental Funds. The MCCC utilizes expert outside scientists and administrators to provide insight and evaluative expertise in the ongoing review of the Cancer Center. The mainstay of the MCCC's planning and evaluation is the input provided by the External Advisory Committee (EAC). This group, reconstituted and expanded following Dr. Diasio's recruitment in the fall of 2006, has been indispensable in guiding the MCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-38
Application #
8382217
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
38
Fiscal Year
2012
Total Cost
$92,586
Indirect Cost
$69,533
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44
Movsas, Benjamin; Hu, Chen; Sloan, Jeffrey et al. (2016) Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol 2:359-67

Showing the most recent 10 out of 948 publications